Viking Therapeutics Inc. (VKTX)
Is Viking Therapeutics Ready For Another Surge?
Viking Therapeutics VKTX has captured the attention of investors, with its stock price skyrocketing over 400% in one year. This remarkable performance stems from the company's promising clinical trial results for VK2735, an investigational weight loss drug that has demonstrated promising efficacy in oral and injectable forms.
Why Viking Therapeutics Stock Topped the Market Today
An analyst waxed bullish on the company's leading pipeline program.
Is Viking Therapeutics Stock a Buy?
Investors have piled into the biotech because of its weight-loss drug candidate. There are already some hugely successful products on pharmacy shelves.
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $61.68, marking a -1.03% move from the previous day.
Is Viking Therapeutics Ready For Another Surge?
Viking Therapeutics NASDAQ: VKTX has captured the attention of investors, with its stock price skyrocketing over 400% in one year. This remarkable performance stems from the company's promising clinical trial results for VK2735, an investigational weight loss drug that has demonstrated promising efficacy in oral and injectable forms.
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $63.13, representing a +1.94% change from its previous close.
Why Viking Therapeutics Stock Was So Healthy on Wednesday
An analyst reiterated his optimistic stance on the biotech. Like many others, he feels its leading investigational drug has great potential.
Viking Therapeutics Is A Buy For Some Investors, But Beware The Sizeable Risks
Viking Therapeutics' weight-loss drug VK2735 shows strong efficacy, likely leading to an acquisition by a large pharmaceutical firm, in my opinion. But the firm faces significant risks and competition. The timeline for a takeover bid may be longer than expected, and the acquisition price could be lower than bullish estimates. Marketing VK2735 independently or finding a strategic partner will be challenging, yet the stock is a buy for patient, risk-tolerant, long-term investors.
Viking Therapeutics Is Having a Year to Remember: Time to Buy?
Viking Therapeutics Inc. NASDAQ: VKTX, a clinical-stage biotechnology company with a market cap approaching $7 billion, is turning heads in 2024. Year to date, the stock has surged an impressive 238%, and its rise over the past 12 months has been even more dramatic, with shares climbing 326%.
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Viking Therapeutics, Inc. (VKTX) closed at $67.10 in the latest trading session, marking a +0.55% move from the prior day.
Why Investors Plowed Into Viking Therapeutics Stock Today
Many investors and prognosticators think one investigational drug in particular has vast potential. If ultimately approved, VK2735 would surely be competitive in a highly popular segment.
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
